The FDA ordered compounding pharmacies to stop making copycat versions of weight loss drugs like Ozempic and Zepbound now ...

Ozempic (semaglutide) is a brand-name injection pen that your doctor may prescribe off-label for PCOS. The drug is not approved for this use, but it may be helpful for symptoms of PCOS.

Wegovy contains the same main ingredient as Ozempic, semaglutide, and is FDA-approved for weight loss in people with obesity or who are overweight with at least one weight-related condition. It is ...

Other off-label uses for semaglutide include nonalcoholic fatty liver disease (NAFLD) and polycystic ovary syndrome (PCOS). To learn more about Ozempic’s off-label use, read this in-depth ...

Please provide your email address to receive an email when new articles are posted on . Semaglutide and tirzepatide were the least cost-effective of four obesity drugs examined in a ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Semaglutide was tied to a small risk of nonarteritic anterior ischemic optic neuropathy (NAION) in adults with type 2 ...

Semaglutide is a drug used for weight loss. Oral tablets and injections are both effective ways to take semaglutide. Oral tablets do not require the use of needles, but you may need to take them ...

What Happens If I Use Expired Semaglutide? This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. Semaglutide — the type 2 diabetes and weight loss medication sold under the brand ...

The agency first declared a shortage of semaglutide, the main ingredient used to make Ozempic and Wegovy, in 2022. The FDA's announcement comes months after drugmaker Novo Nordisk told the agency ...

On February 21, 2025, the US Food and Drug Administration (FDA) revised its shortage categorization of semaglutide, a glucagon-like peptide 1 (GLP-1) medication, marking the shortage as ...

Compounders are on alert after the US Food and Drug Administration (FDA) declared the shortage of semaglutide –the active ingredient in glucagon-like peptide 1 receptor agonist (GLP-1RA ...